4.8 Article

Drug specificity and affinity are encoded in the probability of cryptic pocket opening in myosin motor domains

Journal

ELIFE
Volume 12, Issue -, Pages -

Publisher

eLIFE SCIENCES PUBL LTD
DOI: 10.7554/eLife.83602

Keywords

myosin; specificity; molecular dynamics; cryptic pockets; protein dynamics

Categories

Ask authors/readers for more resources

The design of compounds that can discriminate between closely related target proteins remains a challenge in drug discovery. This study shows that the probability of pocket opening is an important determinant of the potency of the myosin inhibitor blebbistatin. By using Markov state models, it was found that the probability of pocket opening accurately identifies which isoforms are most sensitive to blebbistatin inhibition and predicts blebbistatin binding affinities.
The design of compounds that can discriminate between closely related target proteins remains a central challenge in drug discovery. Specific therapeutics targeting the highly conserved myosin motor family are urgently needed as mutations in at least six of its members cause numerous diseases. Allosteric modulators, like the myosin-II inhibitor blebbistatin, are a promising means to achieve specificity. However, it remains unclear why blebbistatin inhibits myosin-II motors with different potencies given that it binds at a highly conserved pocket that is always closed in blebbistatin-free experimental structures. We hypothesized that the probability of pocket opening is an important determinant of the potency of compounds like blebbistatin. To test this hypothesis, we used Markov state models (MSMs) built from over 2 ms of aggregate molecular dynamics simulations with explicit solvent. We find that blebbistatin's binding pocket readily opens in simulations of blebbistatin-sensitive myosin isoforms. Comparing these conformational ensembles reveals that the probability of pocket opening correctly identifies which isoforms are most sensitive to blebbistatin inhibition and that docking against MSMs quantitatively predicts blebbistatin binding affinities (R-2=0.82). In a blind prediction for an isoform (Myh7b) whose blebbistatin sensitivity was unknown, we find good agreement between predicted and measured IC50s (0.67 mu M vs. 0.36 mu M). Therefore, we expect this framework to be useful for the development of novel specific drugs across numerous protein targets.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available